D'Souza V, Copley-Merriman C. Analysis: first year of the new early access authorization in France. Poster presented at the ISPOR Europe 2022; November 6, 2022. [abstract] Value Health. 2022 Dec 1; 25(12):S342. doi: 10.1016/j.jval.2022.09.1691
Copley-Merriman C, D'Souza V, Arvin-Berod C, Phillips G, Verheesen P, Heyerick A, Stoykov I. Evidence gap analysis of the burden of illness and treatment of pemphigus vulgaris and foliaceus. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S41. doi: 10.1016/j.jval.2022.09.198
Fernandez M, Copley-Merriman C, Arvin-Berod C, Phillips G, Gelinas D, Weiss R, Hofman E, Tse A. Evidence gap analysis of the burden of illness and treatment of chronic inflammatory demyelinating polyneuropathy. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S34. doi: 10.1016/j.jval.2022.09.164
Khan S, Mordin M, Barrows SB, Copley-Merriman K. Similarities & differences in Global Value Dossier (GVD) and Academy of Managed Care Pharmacy (AMCP) dossier development. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 22, 2019. New Orleans, LA.
Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET. Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer. Lung Cancer. 2019 Feb 8;2019:11-20. doi: 10.2147/LCTT.S179349